Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Earliest launch date for Artemis II set for Feb. 8 after cold weather delay: NASA

February 1, 2026

PetPivot Celebrates Love in All Forms This Valentine’s Season with “Valentine’s for the Whole Family (Even the Furry Ones)”

February 1, 2026

I don’t hate the robot barista like I thought I would

February 1, 2026

BexBack Launches No-KYC Crypto Perpetual Futures Trading with 100x Leverage and 100% Deposit Bonus

February 1, 2026

Ottawa wants to get banks, pension funds involved in affordable housing: minister

February 1, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Global Glioma Treatment Market Report 2023-2027 and 2032 Featuring Major Players – Merck & Co, Amgen, F Hoffmann-La Roche, Pfizer, and Teva Pharmaceutical
Press Release

Global Glioma Treatment Market Report 2023-2027 and 2032 Featuring Major Players – Merck & Co, Amgen, F Hoffmann-La Roche, Pfizer, and Teva Pharmaceutical

By News RoomNovember 27, 20234 Mins Read
Global Glioma Treatment Market Report 2023-2027 and 2032 Featuring Major Players – Merck & Co, Amgen, F Hoffmann-La Roche, Pfizer, and Teva Pharmaceutical
Share
Facebook Twitter LinkedIn Pinterest Email
Global Glioma Treatment Market Report 2023-2027 and 2032 Featuring Major Players – Merck & Co, Amgen, F Hoffmann-La Roche, Pfizer, and Teva Pharmaceutical

Dublin, Nov. 27, 2023 (GLOBE NEWSWIRE) — The “Glioma Treatment Global Market Report 2023” report has been added to ResearchAndMarkets.com’s offering.

The global glioma treatment market is expected to grow from $4.37 billion in 2022 to $4.70 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The glioma treatment market is expected to reach $5.99 billion in 2027 at a CAGR of 6.3%.

The glioma treatment market report offers comprehensive statistics, including global market size, regional market shares, the market presence of competitors, detailed market segments within the glioma treatment industry, emerging market trends, opportunities, and additional data essential for success in the glioma treatment sector.

One prominent trend in the glioma treatment market is product innovation, with major companies striving to introduce innovative products to maintain their market positions. For instance, in November 2021, Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, unveiled Delytact, an oncolytic virus therapy for brain cancer, making it the world’s first of its kind. Delytact employs a cancer-fighting virus with a viral genome carrying three triple mutations that enhance replication within cancer cells. This breakthrough treatment is particularly effective against malignant glioma.

Another noteworthy development took place in February 2023 when Kite, a US-based global biopharmaceutical company, acquired Tmunity Therapeutics, further strengthening its position in cell therapy research. This acquisition expands Kite’s portfolio and capabilities by incorporating additional pipeline assets, including an “armored” CAR T technology platform that can enhance the anti-tumor activity of various CAR-T therapies. Tmunity Therapeutics Inc., a US-based biotherapeutics company, focuses on developing novel treatments for diffuse intrinsic pontine glioma.

The glioma treatment market is also anticipated to benefit from the increasing incidence of brain and spinal cord tumors. These tumors comprise uncontrolled masses of abnormal cells in the brain or spinal cord. Glioma treatment plays a crucial role in the management of brain and spinal cord cancers, effectively eliminating remaining cancer cells or residual tumor tissue following surgical procedures.

For example, according to the American Society of Clinical Oncology in March 2023, primary malignant brain and spinal cord tumors were projected to affect approximately 24,810 individuals in the US in 2020, with brain tumors accounting for 85% to 90% of all cases. Globally, an estimated 308,102 individuals received a diagnosis of primary brain or spinal cord tumors in 2020. As a result, the rising incidence of brain and spinal cord tumors is a key driver of growth in the glioma treatment market.

In 2022, North America held the largest share of the glioma treatment market. However, Asia-Pacific is poised to be the fastest-growing region during the forecast period. The glioma treatment market report covers various countries, including Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

Major players in the glioma treatment market are

  • Merck & Co Inc.
  • Amgen Inc.
  • F Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Arbor Pharmaceuticals LLC
  • Amneal Pharmaceuticals Inc.
  • Karyopharm Therapeutics Inc.
  • Bristol-Myers Squibb Co
  • Rigel Pharmaceuticals Inc.
  • Sumitomo Dainippon Pharma Oncology Inc.
  • Thermo Fisher Scientific Inc.
  • Emcure Pharmaceuticals Ltd.
  • Sigma-Aldrich Co

Key Attributes:

Report Attribute Details
No. of Pages 175
Forecast Period 2023 – 2027
Estimated Market Value (USD) in 2023 $4.7 billion
Forecasted Market Value (USD) by 2027 $5.99 billion
Compound Annual Growth Rate 6.3%
Regions Covered Global

Key Topics Covered:

1. Executive Summary

2. Glioma Treatment Market Characteristics

3. Glioma Treatment Market Trends And Strategies

4. Glioma Treatment Market – Macro Economic Scenario
4.1. COVID-19 Impact On Glioma Treatment Market
4.2. Ukraine-Russia War Impact On Glioma Treatment Market
4.3. Impact Of High Inflation On Glioma Treatment Market

5. Glioma Treatment Market Size And Growth
5.1. Global Glioma Treatment Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Glioma Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Glioma Treatment Market Segmentation
6.1. Global Glioma Treatment Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

6.2. Global Glioma Treatment Market, Segmentation By Disease, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • Other Diseases

6.3. Global Glioma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Oral
  • Parenteral
  • Other Routes

6.4. Global Glioma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Surgery
  • Radiation Therapy
  • Chemotherapy
  • Targeted Drug Therapy
  • Other Treatments

6.5. Global Glioma Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

  • Hospitals
  • Specialty Clinics
  • Other End Users

7. Glioma Treatment Market Regional And Country Analysis
7.1. Global Glioma Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global Glioma Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

For more information about this report visit https://www.researchandmarkets.com/r/ord2ng

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Glioma Treatment Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

PetPivot Celebrates Love in All Forms This Valentine’s Season with “Valentine’s for the Whole Family (Even the Furry Ones)”

BexBack Launches No-KYC Crypto Perpetual Futures Trading with 100x Leverage and 100% Deposit Bonus

Mutuum Finance Reports Over 835M MUTM Sold Out and 300% Growth Since Early 2025

Mutuum Finance (MUTM) Raises Over $20.2M as 19,000 Investors Are Testing The V1 Protocol Launch

Global Liver Institute’s Fifth #RareAware Campaign Puts Early Detection at the Center of Care

Mutuum Finance (MUTM) Surpasses $20 Million in Funding Following Launch of Its V1 Protocol on Sepolia Testnet

Barkmeta Provides Timely Analysis on Gold and Silver Amid Market Volatility

The Jay Walker Podcast Debuts at #3 on Apple Podcasts Lifestyle Chart and #12 on iHeart Podcast Charts on Premiere Day

NOCO Healthcare’s Greeley Primary Care Redefines Community-Focused Medicine

Editors Picks

PetPivot Celebrates Love in All Forms This Valentine’s Season with “Valentine’s for the Whole Family (Even the Furry Ones)”

February 1, 2026

I don’t hate the robot barista like I thought I would

February 1, 2026

BexBack Launches No-KYC Crypto Perpetual Futures Trading with 100x Leverage and 100% Deposit Bonus

February 1, 2026

Ottawa wants to get banks, pension funds involved in affordable housing: minister

February 1, 2026

Subscribe to News

Get the latest Canada news and updates directly to your inbox.

Latest News

Antigravity’s 360-degree A1 drone is 15 percent off

February 1, 2026

Mutuum Finance Reports Over 835M MUTM Sold Out and 300% Growth Since Early 2025

February 1, 2026

February’s full Snow Moon set to rise in Ontario

February 1, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version